MSICS Pharma develops and manufactures GMP-grade psilocybin and markets a flagship product, MSX-06, intended for integration within medical treatment protocols. The company holds the only Ministry of Health license in Israel and Europe for GMP psilocybin production for medical use. MSICS is conducting Phase II trials for treatment-resistant depression and OCD and is preparing a large multi-center PTSD trial with four Israeli hospitals while awaiting approval to treat 100 PTSD patients. Internal study results have reportedly shown up to 70% full remission in depression in some cases. The company was founded and is led by brothers Roei Zerahia (CEO) and Omer Zerahia (CBO), who previously led Canndoc. MSICS employs about 12 people and plans to use recent funding to expand production, speed its clinical program, and pursue commercial registration and global supply.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

May 2026